ImageneBio, Inc. Total Assets
ImageneBio, Inc. total assets. Based on the latest financial reports, ImageneBio, Inc. (IMA) holds total assets worth $152.04 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ImageneBio, Inc. stock valuation for the company's overall valuation and market capitalisation.
Total Assets of ImageneBio, Inc. (2018–2025)
Total assets of ImageneBio, Inc. from 2018 to 2025. This chart illustrates how ImageneBio, Inc.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for ImageneBio, Inc. for real-time trading data and today's change.
ImageneBio, Inc. - Asset Composition Analysis
ImageneBio, Inc. Total Assets Breakdown (December 2025)
ImageneBio, Inc. total assets breakdown as of December 2025. ImageneBio, Inc.'s total assets of $152.04 Million consist of 91.7% current assets and 8.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.9% |
| Accounts Receivable | $1.30 Million | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is ImageneBio, Inc.'s working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImageneBio, Inc.'s current assets represent 91.7% of total assets in 2025, a decrease from 96.6% in 2018.
- Cash Position: Cash and equivalents constituted 22.9% of total assets in 2025, down from 87.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
ImageneBio, Inc. Competitors by Total Assets
Key competitors of ImageneBio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ImageneBio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.47 | 13.52 | 8.24 |
| Quick Ratio | 21.47 | 13.52 | 8.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $134.54 Million | $91.69 Million | $221.29 Million |
ImageneBio, Inc. - Advanced Valuation Insights
This section examines the relationship between ImageneBio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | $152.98 Million |
| Market Capitalization | $45.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values ImageneBio, Inc.'s assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ImageneBio, Inc.'s assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ImageneBio, Inc. (2018–2025)
The table below shows the annual total assets of ImageneBio, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $152.98 Million | +8.10% |
| 2024-12-31 | $141.51 Million | -26.33% |
| 2023-12-31 | $192.09 Million | +11.51% |
| 2022-12-31 | $172.26 Million | -30.51% |
| 2021-12-31 | $247.88 Million | +47.19% |
| 2020-12-31 | $168.40 Million | +95.88% |
| 2019-12-31 | $85.97 Million | +315.82% |
| 2018-12-31 | $20.68 Million | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more